Article

FDA Grants Emergency Use Authorization for Novavax Adjuvanted COVID-19 Vaccine as Booster for Adults

Neutralizing antibodies increased by 34- to 27-fold compared to pre-booster levels when administered at 8 or 11 months post-primary series.

The Novavax COVID-19 vaccine, adjuvanted has received emergency use authorization (EUA) from the FDA as a first booster dose at least 6 months after primary vaccination with an authorized COVID-19 vaccine in adults 18 years of age and older who cannot receive an mRNA bivalent COVID-19 booster vaccine.

The decision was based on data from the phase 3 PREVENT-19 trial and from the UK-sponsored COV-BOOST trial. In the PREVENT-19 trial, a single booster dose of the vaccine was administered to healthy adult participants aged 18 years and older approximately 8 or 11 months after their primary series. Following this dose, antibody levels increased significantly relative to pre-booster levels, rising above levels associated with protection in the phase 3 trial. Neutralizing antibodies also increased by 34- to 27-fold compared to pre-booster levels when administered at 8 or 11 months post-primary series.

In the COV-BOOST trial, the Novavax COVID-19 vaccine, adjuvanted increased antibody titers when used as a third dose following initial dosing with another authorized COVID-19 vaccine. Following the booster, local and systemic reactions had a median duration of approximately 2 days.

The incidence of grade 3 or higher adverse events remained relatively low. Safety reporting of reactogenicity events showed an increasing incidence across all 3 doses of the vaccine, often seen with increased immunogenicity. Among participants 18 years of age and older, solicited adverse reactions following administration of a booster dose of the Novavax COVID-19 vaccine, adjuvanted were injection site pain or tenderness (81.1%), fatigue or malaise (63.4%), muscle pain (63%), headache (52.9%), joint pain (30.3%), nausea or vomiting (14.7%), injection site swelling (8.4%), injection site redness (6.3%), and fever (6.3%).

“The US now has access to the Novavax COVID-19 vaccine, adjuvanted, the first protein-based option, as a booster,” said Stanley C. Erck, president and CEO of Novavax, in a press release. “According to CDC data, almost 50% of adults who received their primary series have yet to receive their first booster dose. Offering another vaccine choice may help increase COVID-19 booster vaccination rates for these adults.”

The next step for the vaccine is a policy recommendation from the CDC for its use as a first booster. Doses are available for the United States pending this final step.

Several countries already have policy recommendations allowing use of the vaccine as a heterologous or homologous booster dose. In the United States, the FDA granted an EUA for a 2-dose primary series with the Novavax COVID-19 vaccine in adults aged 18 years and older in July 2022, and for adolescents aged 12 through 17 years in August. The CDC also recommended the vaccine for use as a primary series in both age groups.

REFERENCE

US FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults. News release. Novavax; October 19, 2022. Accessed October 19, 2022. https://ir.novavax.com/2022-10-19-U-S-FDA-Grants-Emergency-Use-Authorization-for-Novavax-COVID-19-Vaccine,-Adjuvanted-as-a-Booster-for-Adults

Related Videos
Healthcare, pharmacist and woman at counter with medicine or prescription drugs sales at drug store.
Image Credit: © Birdland - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com